Insights on Intrepid 2-Yr Mitral TF EFS

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/3a/d5/f8/3ad5f817-8a67-6cfc-f028-a21b2c25ca0e/mza_10571649192769493108.jpg/600x600bb.jpg

Talking Points

TCTMD

193 episodes

1 week ago

Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.

Science

RSS

All content for Talking Points is the property of TCTMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.

Science

https://i1.sndcdn.com/avatars-000211435609-f6to4w-original.jpg

Insights on Intrepid 2-Yr Mitral TF EFS

Talking Points

16 minutes 1 second

3 months ago

Insights on Intrepid 2-Yr Mitral TF EFS

The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.